Labetelol

Reading Document

Medical Text Search

labetalol pharmacology mechanism of action pharmacokinetics

Medical Text Search

labetalol clinical uses indications hypertension dosing

Medical Text Search

labetalol adverse effects contraindications special populations pregnancy

GradeResponse

Medical Text Search

labetalol hypertensive emergency IV dosing protocol acute

Medical Text Search

labetalol beta blocker alpha blocker properties selectivity ratio

GradeResponse

Medical Text Search

labetalol oral dosing titration heart failure contraindication side effects

Medical Text Search

labetalol aortic dissection preeclampsia eclampsia treatment

Labetalol

Mechanism of Action

Labetalol is a combined α₁- and non-selective β-adrenergic receptor antagonist. Its key property is its dual blockade:

Receptor	Effect
β₁ (cardiac)	↓ Heart rate, ↓ contractility, ↓ AV conduction
β₂ (vascular/bronchial)	Bronchospasm risk; blocks vasodilatory β₂
α₁ (vascular)	Peripheral vasodilation → ↓ SVR

The α:β blockade ratio is approximately 1:5–1:7 orally and 1:3 intravenously. This means beta-blockade predominates, but the alpha component provides vasodilation that prevents reflex tachycardia — a key advantage over pure beta-blockers.

Pharmacokinetics

Bioavailability: ~25% oral (extensive first-pass metabolism)
Onset: IV — 2–5 min; oral — 20 min to 2 hours
Duration: IV — 2–4 hours; oral — 8–12 hours
Metabolism: Hepatic (glucuronide conjugation)
Half-life: ~6–8 hours
Elimination: Primarily renal (metabolites); dose adjustment in hepatic impairment

Clinical Indications

1. Hypertension (Chronic)

Oral dosing: 100 mg twice daily, titrated up to 2400 mg/day in divided doses
Useful in patients where both heart rate control and vasodilation are desired

2. Hypertensive Emergency (IV)

Bolus: 20 mg IV over 2 minutes; may repeat 40–80 mg every 10 min (max cumulative 300 mg)
Infusion: 0.5–2 mg/min, titrated to BP response
Advantages: Rapid onset, titratable, does not cause reflex tachycardia (Harrison's, p. 2087)

3. Hypertension in Pregnancy / Preeclampsia

First-line oral antihypertensive in pregnancy (alongside nifedipine and methyldopa) per ESC/ESH guidelines
Preferred over atenolol (which causes fetal growth restriction)
Safe in breastfeeding (Management of Elevated Blood Pressure and Hypertension, p. 59)

4. Aortic Dissection

IV labetalol is a first-line agent — reduces both heart rate and BP simultaneously (Harrison's, p. 2106)
Target: HR < 60 bpm, SBP 100–120 mmHg

5. Pheochromocytoma Crisis (IV)

IV labetalol (1–2 mg/kg bolus over 1 min followed by infusion) can manage adrenergic crisis with the advantage of avoiding tachycardia via beta-blockade
Caution: Should NOT be used as initial/sole therapy for pheochromocytoma — its α:β ratio is insufficient to prevent paradoxical hypertension from unopposed α-stimulation; alpha-blockade must be established first (ESC Guidelines, p. 72; PPGL Surveillance Guidelines, p. 11)

6. Other

Ischemic heart disease (rate control)
Sympathomimetic overdose/toxicity

Contraindications

Absolute	Relative
Decompensated heart failure	Mild-moderate reactive airway disease
Cardiogenic shock	Peripheral vascular disease
Severe bradycardia / high-degree AV block	Diabetes (masks hypoglycemia symptoms)
Sick sinus syndrome	Chronic obstructive pulmonary disease
Asthma (significant bronchospasm risk)	—

Adverse Effects

Cardiovascular: Bradycardia, orthostatic hypotension, heart block
Respiratory: Bronchospasm (non-selective β₂ blockade)
CNS: Fatigue, dizziness, headache
Metabolic: Blunted hypoglycemic awareness in diabetics
Hepatic: Rare drug-induced liver injury (hepatotoxicity) — monitor LFTs with long-term use
Scalp tingling/paresthesias: A characteristic complaint reported by some patients
Abrupt withdrawal can precipitate rebound hypertension or angina

Special Populations

Population	Consideration
Pregnancy	First-line; safe (avoid atenolol)
Renal impairment	No dose adjustment needed
Hepatic impairment	Reduce dose; heavily hepatically metabolized
Elderly	Start low; orthostatic hypotension risk
Pheochromocytoma	IV use only after adequate alpha-blockade is established
Heart failure	Avoid in decompensated HF; stable HF — use with caution

Key Clinical Pearls

Unlike pure beta-blockers, labetalol does not increase SVR and typically does not worsen peripheral vascular disease as much
It does not cause reflex tachycardia — useful in aortic dissection and post-op hypertension
In pregnancy, it is preferred IV agent for acute severe hypertension alongside hydralazine and nifedipine
Do not use as initial monotherapy for pheochromocytoma — always establish alpha-blockade first to avoid paradoxical hypertensive crisis

This is a shared conversation. Sign in to Orris to start your own chat.